Novel 2-methoxyestradiol analogues with antitumor activity

Area of Science:

• Pharmacology
• Oncology
• Biochemistry

Background:

• 2-Methoxyestradiol (2-ME2) is an endogenous estrogen metabolite with demonstrated antiangiogenic and antitumor properties.
• 2-ME2 is under investigation in clinical trials for various cancers, highlighting its therapeutic potential.
• Developing more potent analogues of 2-ME2 could lead to improved cancer treatments.

Purpose of the Study:

• To synthesize and evaluate novel 2-ME2 analogues for antiangiogenic and antitumor activities.
• To compare the efficacy of these analogues against the parent compound, 2-ME2.
• To investigate the mechanism of action of the most promising analogues.

Main Methods:

• In vitro assays assessing endothelial cell proliferation and invasion.
• In vitro cytotoxicity and proliferation assays against multiple tumor cell lines.
• In vivo antitumor activity assessment using a murine xenograft model.
• Mechanism of action studies including tubulin assembly, Bcl-2 phosphorylation, and MAPK signaling.

Main Results:

• Several novel 2-ME2 analogues exhibited significant inhibition of endothelial cell proliferation and invasion, with 2-methoxy-14-dehydroestradiol (14-dehydro-2-ME2) being 6-15 times more potent than 2-ME2.
• Analogues demonstrated potent inhibition of tumor cell proliferation and cytotoxicity, with 14-dehydro-2-ME2 showing approximately 15-fold greater potency than 2-ME2.
• In vivo studies showed antitumor activity for three analogues, with 14-dehydro-2-ME2 and 2-methoxyestradiol-15 alpha,16 alpha-acetonide achieving 29.4% and 26.7% tumor burden inhibition, respectively.
• Mechanism studies revealed that analogues disrupt mitotic spindles, cause mitotic arrest, depolymerize microtubules, and inhibit tubulin assembly, similar to 2-ME2, while also inducing Bcl-2 phosphorylation and activating MAPK pathways.

Conclusions:

• Novel 2-ME2 analogues possess enhanced antiangiogenic and antitumor activities compared to 2-ME2.
• These analogues represent promising candidates for further development as anticancer therapeutics.
• The mechanism of action involves disruption of microtubule dynamics and induction of apoptosis via Bcl-2 and MAPK pathways.